A Cross-Sectional Study of Serum Ferritin Levels in Vietnamese Adults with Metabolic Syndrome

Figures & data

Table 1 Diagnostic Criteria for Metabolic Syndrome According to IDF/AHA/NHLBL/WHF/IAS/IASO-2009.¹⁰

Criteria	Reference Values
Increase waist circumference	Male: ≥ 90cm
	Female: ≥ 80cm (South Asian standard)
Elevated triglyceride^† or drug treatment for elevated triglyceride	≥150mg/dl (1,7mmol/l)
Reduced HDL-C^† or drug treatment for reduced HDL-C	Male <40mg/dl (1.03mmol/l)
	Female <50mg/dl (1.29mmol/l)
Hypertension or drug treatment for hypertension	Systolic ≥ 130mmHg and/or diastolic ≥ 85mmHg
Elevated fasting glucose or drug treatment for diabetes	≥ 100mg/dl (5.6mmol/l)

Notes: Data adapted from Alberti.^{10 †}The most commonly used drugs to treat elevated triglyceride and reduced HDL-C are the fibrate group and the nicotinic acid group. Patients taking either of these drugs or high doses of omega 3 fatty acids were assessed as having an equivalent standard for elevated triglyceride and reduced HDL-C.

Abbreviation: HDL-C, high density lipoprotein cholesterol.

Table 2 Characteristics of Age and Gender Distribution

	Control Group (n=103)	Study Group (n=104)	p-value
Age group (years)
< 60	41 (39.8%)	33 (31.7%)	0.2860
≥ 60	62 (60.2%)	71 (68.3)
Gender
Male	45 (43.7%)	52 (50.0%)	0.4410
Female	58 (46.3%)	52 (50.0%)
Age (years)
Overall	60.02 ± 19.06	66.36 ± 14.74	0.0080
Male	62.78 ± 18.91	64.83 ± 17.05	0.4136
Female	57.88 ± 19.07	67.88 ± 11.98	< 0.001

Table 3 Anthropometric Indicators by Gender for 2 Groups with and without Metabolic Syndrome

Index	Control Group (n=103)	Study Group (n=104)	p
	Male
Height (m)	1.65 ± 0.45	1.65 ± 0.57	1.0000
Weight (kg)	58.78 ± 7.66	61.60 ± 9.65	0.0209
BMI (kg/m^2)	21.61 ± 2.33	22.56 ± 3.07	0.0130
Waist circumference (cm)	79.78 ± 3.87	85.13 ± 5.24	< 0.001
	Female
Height (m)	1.54 ± 0.05	1.55 ± 0.04	0.1135
Weight (kg)	50.00 ± 7.13	51.17 ± 5.45	0.1859
BMI (kg/m^2)	20.95 ± 2.65	21.34 ± 2.35	0.2638
Waist circumference (cm)	76.93 ± 4.68	80.96 ± 3.42	< 0.001

Abbreviation: BMI, body mass index.

Table 4 The Ratio of the Components of the Metabolic Syndrome

Characteristics of Metabolic Syndrome	Control Group (n=103)	Study Group (n=104)
Central obesity	17 (16.5%)	61 (58.7%)	<0.001
Hypertension	10 (9.70%)	94 (90.38%)	<0.001
Increased triglycerides	14 (16.59%)	88 (84.62%)	<0.001
Reduced HDL-C	33 (32.04%)	61 (58.65%)	<0.001
Increased fasting blood glucose	19 (18.45%)	79 (75.96%	<0.001

Abbreviation: HDL-C, high density lipoprotein cholesterol.

Table 5 Serum Ferritin Status in the Study Group

Status		Control Group (n=103)		Study Group (n=104)		p
		n	%	n	%
Increased serum ferritin	General	25	24.26	95	91.35	< 0.001
	Male	11	10.68	50	48.08	< 0.001
	Female	14	13,58	45	43.27	<0.001
Mean serum ferritin concentration	General	124.55 ± 63.95		391.62 ± 181.97		< 0.001
	Male	136.03 ±72.23		453.064 ± 161.75		< 0.001
	Female	115.64 ± 55.73		330.17 ± 181.71		<0.001

Table 6 Mean Serum Ferritin Concentration of the Group of 3 Common Metabolic Syndrome Components

Study Group		Control Group	p
Mean Serum Ferritin Concentration		Mean Serum Ferritin Concentration
Increased G – Increased TG – Hypertension (n=53)	399.11 ± 177.62	124.55 ± 63.95	< 0.001
Increased TG – Hypertension – Reduced HDL-C (n=45)	379.60 ± 186.40	124.55 ± 63.95	< 0.001
Increased Waist circumference – Increased TG – Hypertension (n=41)	371.20 ± 191.79	124.55 ± 63.95	< 0.001
Increased G – Increased TG – Reduced HDL-C (n= 39)	378.82 ± 156.81	124.55 ± 63.95	< 0.001
Increased G– Hypertension – Reduced HDL-C (n= 37)	354.86 ± 172.99	124.55 ± 63.95	< 0.001
Increased G – Increased Waist circumference – Hypertension (n= 34)	346.24 ± 173.88	124.55 ± 63.95	< 0.001

Abbreviations: G, glucose; TG, triglyceride; HDL-C, high density lipoprotein cholesterol.

Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120(16):1640–1645. doi:10.1161/CIRCULATIONAHA.109.192644

 PubMed Web of Science ®Google Scholar